Status:
COMPLETED
Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer
Lead Sponsor:
University of Miami
Conditions:
Cervical Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
Nelfinavir will increase the efficacy of Cisplatin based chemo- radiation therapy for locally advanced cervical cancer.
Detailed Description
Despite cisplatin chemoradiation, 40-50% of women with locally advanced cervical cancer will die from their disease. The evaluation of new chemoradiation regimens have since included cisplatin to furt...
Eligibility Criteria
Inclusion
- All patients with primary, previously untreated, histologically confirmed invasive carcinoma of the uterine cervix (any cell type). Clinical stages IIA, IIB, IIIA, IIIB, IVA.
- Patients must have adequate bone marrow, renal and hepatic function:
- ANC ≥ 1,500/μL;
- Platelet count ≥ 100,000/μL;
- Creatinine \< 2.0 mg/dL;
- Total Bilirubin ≤ 1.5 times normal;
- SGOT ≤ 3 times normal.
- Patients with a GOG Performance Status of 0, 1, or 2.
- Patients with ureteral obstruction must be treated with stent or nephrostomy tube.
- Patients must be entered within eight weeks of diagnosis.
- Patients of childbearing potential must use an effective form of birth control."Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive measures should be used during therapy with VIRACEPT. "
- Seronegative HIV status.
- Patients must be at least 18 years of age.
- Patients must have signed an approved informed consent and authorization permitting release of personal health information.
Exclusion
- Patients with Stage IA, IB or IVB disease.
- Patients who have known metastases to other organs outside the radiation field at the time of the original clinical and surgical staging.
- Patients who have received previous pelvic or abdominal radiation, cytotoxic chemotherapy, or previous therapy of any kind for this malignancy.
- Patients with septicemia or severe infection.
- Patients who have circumstances that will not permit completion of this study or the required follow-up.
- Patients who are pregnant at the time of diagnosis and do not wish pregnancy termination prior to initiation of treatment.
- Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields.
- Patients with other concomitant malignancies (with the exception of non-melanoma skin cancer), who had (or have) any evidence of other cancer present within the last 5 years.
- Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).
- Patients with poorly controlled diabetes mellitus despite medication.
- Patients taking anti-arrhythmic agents such as amiodarone, quinidine, rifampin, ergot derivatives such as ergotamine, St Johs Wort, HMG-CoA reductase inhibitors such as lovastatin, neuroleptic such as pimozide, sedatives such as midazolam and triazolam among other CYP3A4 and CYP2C19 substrates.
- Patients with Phenylketonuria.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT01485731
Start Date
January 1 2012
End Date
February 1 2015
Last Update
June 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami
Miami, Florida, United States, 33136